Please login to the form below

Not currently logged in
Email:
Password:

Ignyta

This page shows the latest Ignyta news and features for those working in and with pharma, biotech and healthcare.

Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review

Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review

Roche acquired rights to entrectinib when it bought Ignyta for $1.7bn just over a year ago, having licensed rights to the drug in a $1.55bn deal a few weeks

Latest news

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Pharma deals in March 2015 Pharma deals in March 2015

    Two days' later Teva acquired four oncology development programmes (the most advanced in phase I/II) from Ignyta for $42m.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics